Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan

PHASE4CompletedINTERVENTIONAL
Enrollment

625

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 20, 2017

Study Completion Date

February 3, 2017

Conditions
DehydrationGastroenteritisVomitingDiarrhea
Interventions
DRUG

Ondansetron

Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.

DRUG

Placebo

Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.

Trial Locations (2)

Unknown

Aga Khan University Hospital, Karachi

Aga Khan Hospital for Women and Children (AKHWC), Kharadar, Karachi

All Listed Sponsors
collaborator

Thrasher Research Fund

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Aga Khan University

OTHER

lead

Dr. Stephen Freedman

OTHER

NCT01870635 - Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan | Biotech Hunter | Biotech Hunter